deferoxamine has been researched along with CKD-MBD in 24 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 7.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
| "Evidence has emerged over the last several years indicating that aluminum accumulation in patients with chronic renal failure can cause certain forms of renal osteodystrophy, in particular osteomalacia and an aplastic lesion." | 4.77 | Aluminum and renal osteodystrophy. ( Coburn, JW; Nebeker, HG, 1986) |
| "Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 3.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
| " Their prevention relies on adequate treatment of tapwater and definitive exclusion of long term administration of aluminum phosphate binders." | 2.41 | [Renal osteodystrophy (3); its treatment in dialysis patients]. ( Arsenescu, I; Benamar, L; el Esper, N; Fournier, A; Ghitu, S; Morinière, P; Oprisiu, R; Said, S; Tataru Albu, A, 2000) |
| "The management of renal osteodystrophy should address all the pathogenetic mechanisms." | 2.38 | Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients. ( Tzamaloukas, AH, 1990) |
| "In conclusion, the distribution of renal osteodystrophy in our study was different from that of Western countries in pre-dialysis patients." | 1.30 | Renal osteodystrophy in pre-dialysis patients: ethnic difference? ( Ha, SK; Kim, DH; Kim, HS; Kim, SJ; Kwak, YS; Ma, KA; Sherrard, DJ; Shin, KT; Shin, SK, 1999) |
| " Using reversed osmosis in dialysis the high aluminium levels in bone result mainly from the long-term use of phosphate binders." | 1.27 | [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure]. ( Beck, G; Gmeiner, R; König, P; Lechleitner, P, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (54.17) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| London, GM | 1 |
| Marty, C | 1 |
| Marchais, SJ | 1 |
| Guerin, AP | 1 |
| Metivier, F | 1 |
| de Vernejoul, MC | 1 |
| Yamamoto, I | 2 |
| Kawamura, Y | 1 |
| Hirano, K | 1 |
| Hayakawa, H | 1 |
| Shigematu, T | 1 |
| Milliner, DS | 1 |
| Nebeker, HG | 2 |
| Ott, SM | 1 |
| Andress, DL | 1 |
| Sherrard, DJ | 2 |
| Alfrey, AC | 1 |
| Slatopolsky, EA | 1 |
| Coburn, JW | 2 |
| Ackrill, P | 1 |
| Day, JP | 1 |
| Garstang, FM | 1 |
| Hodge, KC | 1 |
| Metcalfe, PJ | 1 |
| Benzo, Z | 1 |
| Hill, K | 1 |
| Ralston, AJ | 1 |
| Ball, J | 1 |
| Denton, J | 1 |
| Jorgetti, V | 1 |
| Soeiro, NM | 1 |
| Mendes, V | 1 |
| Pereira, RC | 1 |
| Crivellari, ME | 1 |
| Coutris, G | 1 |
| Borelli, A | 1 |
| Leite, MO | 1 |
| Nussenzweig, I | 1 |
| Marcondes, M | 1 |
| Cronin, RE | 1 |
| Mathias, R | 1 |
| Salusky, I | 1 |
| Harman, W | 1 |
| Paredes, A | 1 |
| Emans, J | 1 |
| Segre, G | 1 |
| Goodman, W | 1 |
| Jablonski, G | 1 |
| Klem, KH | 1 |
| Danielsen, CC | 1 |
| Mosekilde, L | 1 |
| Gordeladze, JO | 1 |
| Shin, SK | 1 |
| Kim, DH | 1 |
| Kim, HS | 1 |
| Shin, KT | 1 |
| Ma, KA | 1 |
| Kim, SJ | 1 |
| Kwak, YS | 1 |
| Ha, SK | 1 |
| Ghitu, S | 1 |
| Oprisiu, R | 1 |
| Benamar, L | 1 |
| Said, S | 1 |
| Tataru Albu, A | 1 |
| Arsenescu, I | 1 |
| el Esper, N | 1 |
| Morinière, P | 1 |
| Fournier, A | 1 |
| DeVita, MV | 1 |
| Rasenas, LL | 1 |
| Bansal, M | 1 |
| Gleim, GW | 1 |
| Zabetakis, PM | 1 |
| Gardenswartz, MH | 1 |
| Michelis, MF | 1 |
| Tzamaloukas, AH | 1 |
| Moriya, A | 1 |
| Motomiya, Y | 1 |
| Joko, M | 1 |
| Okada, H | 1 |
| Saka, M | 1 |
| Yoshida, K | 1 |
| Kaneko, Y | 1 |
| Hashimoto, M | 1 |
| Maruyama, Y | 1 |
| Ozono, S | 1 |
| Verbeelen, D | 1 |
| Smeyers-Verbeke, J | 1 |
| van Hooff, I | 1 |
| de Roy, G | 1 |
| Oppenheim, WL | 1 |
| Namba, R | 1 |
| Goodman, WG | 1 |
| Salusky, IB | 1 |
| Charhon, S | 1 |
| el Yafi, S | 1 |
| Gaillard, M | 1 |
| Beruard, M | 1 |
| Janin, G | 1 |
| Accominotti, M | 1 |
| Traeger, J | 1 |
| Meunier, PJ | 1 |
| Slatopolsky, E | 1 |
| O'Brien, AA | 1 |
| Moore, DP | 1 |
| Keogh, JA | 1 |
| Lechleitner, P | 1 |
| Gmeiner, R | 1 |
| Beck, G | 1 |
| König, P | 1 |
| Hino, M | 2 |
| Shigeno, C | 1 |
| Aoki, J | 1 |
| Torizuka, K | 1 |
| Iwamoto, N | 2 |
| Yamazaki, S | 2 |
| Fukuda, T | 2 |
| Kondo, M | 2 |
| Yamamoto, N | 2 |
| Swartz, R | 1 |
| Dombrouski, J | 1 |
| Burnatowska-Hledin, M | 1 |
| Mayor, G | 1 |
| Ono, T | 1 |
| Hiratake, Y | 1 |
| Masugi, Y | 1 |
| Kubo, Y | 1 |
| Ham, KN | 1 |
| Brown, DJ | 1 |
| Dawborn, JK | 1 |
| Johnson, CI | 1 |
| Nelson, S | 1 |
| Xipell, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699] | Phase 3 | 176 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to Financial problem) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for deferoxamine and CKD-MBD
| Article | Year |
|---|---|
[Therapy for ROD and measurement of the bone mass].
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone D | 2004 |
Southwestern Internal Medicine Conference: bone disease in kidney failure: diagnosis and management.
Topics: Aged; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Calcium; Chelating Agents; Chronic Kidney D | 1993 |
[Renal osteodystrophy (3); its treatment in dialysis patients].
Topics: Aluminum; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Def | 2000 |
Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
Topics: Aluminum; Biopsy; Bone and Bones; Bone Diseases; Calcitriol; Chronic Kidney Disease-Mineral and Bone | 1990 |
Aluminum and renal osteodystrophy.
Topics: 24,25-Dihydroxyvitamin D 3; Aluminum; Animals; Bone and Bones; Calcitriol; Caseins; Chronic Kidney D | 1986 |
19 other studies available for deferoxamine and CKD-MBD
| Article | Year |
|---|---|
Arterial calcifications and bone histomorphometry in end-stage renal disease.
Topics: Aluminum; Bicarbonates; Bone and Bones; Bone Density; Calcium; Calcium Phosphates; Chronic Kidney Di | 2004 |
Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.
Topics: Aluminum; Bone Development; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Humans; | 1984 |
Treatment of fracturing renal osteodystrophy by desferrioxamine.
Topics: Adult; Aged; Aluminum; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamin | 1983 |
Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus.
Topics: Adolescent; Adult; Alkaline Phosphatase; Aluminum; Bone Remodeling; Calcium; Chronic Kidney Disease- | 1994 |
Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.
Topics: Adolescent; Aluminum; Biopsy; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Defe | 1993 |
Aluminium-induced bone disease in uremic rats: effect of deferoxamine.
Topics: Adenylyl Cyclases; Aluminum; Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases; Bone R | 1996 |
Renal osteodystrophy in pre-dialysis patients: ethnic difference?
Topics: Adult; Aged; Asian People; Bone and Bones; Chelating Agents; Chronic Kidney Disease-Mineral and Bone | 1999 |
Assessment of renal osteodystrophy in hemodialysis patients.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Aluminum; Biopsy; Calcium; Chronic Kidney Disease-Mine | 1992 |
[The diagnostic critical value in DFO low dose loading test on patient with aluminum accumulation compared to each parameter of ROD].
Topics: Adolescent; Adult; Aged; Aluminum; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; F | 1990 |
Vitamin D, desferrioxamine and aluminum-induced bone disease in uremic rats.
Topics: Aluminum; Animals; Bone and Bones; Brain Chemistry; Chronic Kidney Disease-Mineral and Bone Disorder | 1989 |
Aluminum toxicity complicating renal osteodystrophy. A case report.
Topics: Aluminum; Bone and Bones; Child, Preschool; Chronic Kidney Disease-Mineral and Bone Disorder; Combin | 1989 |
Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy.
Topics: Adult; Aluminum; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Female; Humans; Inf | 1988 |
The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
Topics: Adult; Aluminum; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; | 1987 |
The response of the normochromic normocytic anaemia of chronic renal failure to desferrioxamine.
Topics: Adult; Aged; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Femal | 1987 |
[Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
Topics: Adult; Aluminum; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Female; Humans; Kid | 1987 |
[Aluminum associated bone disease in patients undergoing long-term hemodialysis].
Topics: Adult; Aluminum; Bone and Bones; Calcinosis; Chronic Kidney Disease-Mineral and Bone Disorder; Defer | 1986 |
Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
Topics: Adult; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Erythrocyte | 1987 |
Clinical features of aluminum-associated bone disease in long-term hemodialysis patients.
Topics: Adult; Aged; Aluminum; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamin | 1986 |
Dialysis osteomalacia: a possible role for zirconium as well as aluminium.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Glomerulonephritis; Humans; Osteomal | 1985 |